Oct 26, 2007 by Brian Orelli, PhDThis Just In: Mergers Do Indeed Lower CostsThermo Fisher merger continues to progress nicely.
Oct 25, 2007 by Brian Orelli, PhDTime to Invest in Stents?New data gives a peek into how the players are posed to do.
Oct 25, 2007 by Brian Orelli, PhDFrom the Fire Line to the Bottom LineIn San Diego, displaced employees might affect production at some of the companies you own.
Oct 25, 2007 by Brian Orelli, PhDTurnaround at AffymetrixIncreasing revenue and decreasing expenses -- who could ask for more?
Oct 25, 2007 by Brian Orelli, PhDReddy for a Rollercoaster RideDr. Reddy sees a dip in revenue from the loss of authorized generics.
Oct 24, 2007 by Brian Orelli, PhDIllumina's Illuminating ResultsThere was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
Oct 23, 2007 by Brian Orelli, PhDOld Merck on New DrugsThe pre-VIOXX Merck is back, double-digit sales growth shows.
Oct 23, 2007 by Brian Orelli, PhDSchering Ploughed DownSchering gets a haircut after missing earnings.
Oct 22, 2007 by Brian Orelli, PhDNew Warnings Won't Sink ED Drug SalesShockingly, new safety warnings won't hurt erectile dysfunction drugs.
Oct 19, 2007 by Brian Orelli, PhDBaxter Gets Pumped UpThe medical-device maker puts in a nice quarter despite its recent recall trouble.
Oct 18, 2007 by Brian Orelli, PhDAmylin: Waiting on the FutureResearch and development costs drag down the drug developer's bottom line.
Oct 17, 2007 by Brian Orelli, PhDFDA Warning Might Be a Buying OpportunityThe reduction in patients for Amylin's Byetta diabetes drug could be small.
Oct 17, 2007 by Brian Orelli, PhDJ&J Puts Band-Aid on the QuarterJ&J gets dragged down by restructuring charges.
Oct 16, 2007 by Brian Orelli, PhDNot a Blockbuster -- YetMerck gains marketing approval for its newest HIV drug.
Oct 8, 2007 by Brian Orelli, PhDNew FDA Regulations for DrugmakersThey have few side effects for generic-drug makers.
Oct 8, 2007 by Brian Orelli, PhDPozen Submits Safety DataWill Pozen's response to its second approvable letter be enough?
Oct 5, 2007 by Brian Orelli, PhDMerck's Next Blockbuster?Merck's cholesterol drug comes back from testing with no side effects.
Oct 5, 2007 by Brian Orelli, PhDA Guide to Innovative TechnologyOne magazine's winners might affect the bottom lines of these life sciences companies.
